Hormonal
Six-month treatment with the GLP-1 analog liraglutide prevents the decline of cerebral glucose metabolism (CMRglc) in patients with Alzheimer's disease, although it does not significantly reduce amyloid-beta deposition or improve cognitive scores.
For patients with Alzheimer's, a 6-month course of liraglutide (a GLP-1 analog) may help maintain brain glucose metabolism, which is linked to cognitive function and disease progression. However, this treatment did not reduce amyloid plaques or improve cognitive test scores in this specific study. Patients should be aware of potential gastrointestinal side effects like nausea, which are often temporary, and the need for daily injections.
We conclude that the GLP-1 analog treatment prevented the decline of CMRglc that signifies cognitive impairment, synaptic dysfunction, and disease evolution. We draw no firm conclusions from the Aβ load or cognition measures, for which the study was underpowered.
Why this rating
Randomized, placebo-controlled, double-blind design, but small sample size (n=38), short duration (6 months), and underpowered for secondary outcomes.
Source
In Alzheimer’s Disease, 6-Month Treatment with GLP-1 Analog Prevents Decline of Brain Glucose Metabolism: Randomized, Placebo-Controlled, Double-Blind Clinical Trial
Michael Gejl et al. · Frontiers in Aging Neuroscience · 2016
DOI 10.3389/fnagi.2016.00108
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →